While vaccine-makers race to test their shots against the variant, the monoclonal antibody sotrovimab Sotrovimab is the first monoclonal antibody showing preclinical efficacy against all COVID-19 variants

like to take this opportunity to thank all our French partners who trust us in the generation of their monoclonal antibodies against small molecules and transmembrane receptors! #technology #lifescience #immunology #antibodies #medicine #cancer #innovation #gpcr #synabs #monoclonalantibodies

far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and monoclonal antibodies for the treatment of cancer, infections, metabolic disorders or inflammatory diseases.

IX / Technology capsule: Light on aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing monoclonal antibody drugs against GPCRs and other multi-pass transmembrane technology, demonstrated in the success of COVID-19 vaccines, is emerging as a promising method for antibody These studies show that mRNA immunization yields higher antibody titers and greater epitope diversity These examples underscore the potential of NovoiSMART technology in developing highly specific antibodies

postdoctoral work investigated the role of the G protein transducin in visual transduction using blocking monoclonal antibodies.

muscle , Allergic bronchopulmonary aspergillosis , Allergic fungal rhinosinusitis , Allergic rhinitis , Antibody-dependent receptor 3 , Mas-related family of G-protein-coupled receptors , Mitogen-activated protein kinase , Monoclonal antibody , Monocyte chemoattractant protein-4 , MrgprA , MrgprA3 , MrgprCr11 , NGF , NMU , NP , Na(v